Regístrese
Buscar en
Gastroenterología y Hepatología (English Edition)
Toda la web
Inicio Gastroenterología y Hepatología (English Edition) Granulocyte and monocyte apheresis in inflammatory bowel disease: The patients...
Journal Information
Vol. 41. Issue 7.
Pages 423-431 (August 2018)
Share
Share
Download PDF
More article options
ePub
Visits
0
Vol. 41. Issue 7.
Pages 423-431 (August 2018)
Original article
DOI: 10.1016/j.gastre.2018.04.020
Granulocyte and monocyte apheresis in inflammatory bowel disease: The patients’ point of view
Granulocito-monocito aféresis en la enfermedad inflamatoria intestinal: el punto de vista de los pacientes
Visits
0
Iago Rodríguez-Lagoa,
Corresponding author
iago.r.lago@gmail.com

Corresponding author at: Gastroenterology Department, Hospital de Galdakao, Barrio Labeaga s/n, 48960 Galdakao (Vizcaya), Spain.
, José Manuel Benítezb, Valle García-Sánchezb, Ana Gutiérrezc,d, Laura Semperec, Daniel Ginarde, Manuel Barreiro-de Acostaf, José Luis Cabriadaa
a Gastroenterology Department, Hospital de Galdakao, Galdakao (Vizcaya), Spain
b Gastroenterology Department, Hospital Universitario Reina Sofía, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Córdoba (Córdoba), Spain
c Gastroenterology Department, Hospital Universitario de Alicante, Alicante (Alicante), Spain
d CIBEREHD (Centro de Investigación Biomédica en Red en el Área temática de Enfermedades Hepáticas), Instituto de Salud Carlos III, Madrid, Spain
e Gastroenterology Department, Hospital Universitari Son Espases, Palma (Islas Baleares), Spain
f Gastroenterology Department, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela (Galicia), Spain
This item has received
0
Visits
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Tables (3)
Table 1. Patient characteristics.
Table 2. Questionnaire results.
Table 3. Questionnaire results about satisfaction with granulocyte–monocyte apheresis.
Show moreShow less
Additional material (2)
Abstract
Background

Granulocyte and monocyte apheresis is the main non-pharmacological treatment for inflammatory bowel disease (IBD), but we do not know how well accepted it is by patients in our setting.

Aim

To determine how granulocyte and monocyte apheresis is perceived by patients in clinical practice in Spain.

Methods

Outpatients treated with granulocyte and monocyte apheresis in five IBD Units in Spain were asked to fill in a 14-item questionnaire.

Results

Fifty-two patients completed the questionnaire (88% ulcerative colitis, 12% Crohn's disease; 44% female; age 35 years [IQR 23–51]). Granulocyte and monocyte apheresis was generally well tolerated and well accepted. Very few of the participants regarded the length of the sessions as a limitation. The gastrointestinal symptoms, however, were a frequent concern, both in terms of attending to receive treatment and during the sessions. Overall, 44% were satisfied with the treatment effectiveness. Sixty percent (60%) claimed to be satisfied with the therapy overall, but this was influenced by the patients’ clinical response to the therapy. Eighty-two percent (82%) of participants said they would agree to be treated with this technique again in the future, regardless of the response to the treatment.

Conclusions

Granulocyte and monocyte apheresis is well tolerated and accepted by patients with IBD. Although we found no significant differences according to type of IBD or apheresis regimen, patient perception was affected by clinical effectiveness.

Keywords:
Crohn's disease
Granulocyte–monocyte apheresis
Questionnaires
Ulcerative colitis
Abbreviations:
GMA
UC
CD
IBD
Resumen
Introducción

La leucocitoaféresis constituye el principal tratamiento no farmacológico para la enfermedad inflamatoria intestinal (EII), pero no conocemos su grado de aceptación por los pacientes en nuestro entorno.

Objetivo

Conocer la percepción de los pacientes sobre la leucocitoaféresis en la práctica clínica en España.

Métodos

Se ofreció un cuestionario de 14 preguntas a los pacientes ambulatorios tratados con leucocitoaféresis en 5 unidades de EII en España.

Resultados

Cincuenta y dos pacientes respondieron el cuestionario (88% colitis ulcerosa, 12% enfermedad de Crohn; 44% mujeres, 35 años [RIQ: 23-51]). La leucocitoaféresis fue bien tolerada de forma global y con un alto grado de aceptación. La mayoría de pacientes no percibía la duración de las sesiones como una limitación. En cambio, los síntomas digestivos eran una preocupación habitual, tanto para acudir al tratamiento como durante las sesiones. Un 44% estaban satisfechos con la efectividad del tratamiento. El 60% contestaron que estaban satisfechos con la técnica de forma global, pero esto estaba influenciado por la respuesta clínica que habían experimentado. Un 82% estarían dispuestos a ser tratados de nuevo con la técnica, independientemente de la respuesta al tratamiento.

Conclusiones

La leucocitoaféresis es una técnica bien tolerada y aceptada por los pacientes con EII. A pesar de que no encontramos diferencias según el tipo de EII o la pauta de tratamiento, sí encontramos una percepción diferente según la efectividad de la técnica.

Palabras clave:
Enfermedad de Crohn
Leucocitoaféresis
Cuestionario
Colitis ulcerosa

Article

These are the options to access the full texts of the publication Gastroenterología y Hepatología (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Gastroenterología y Hepatología (English Edition)

Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
Supplemental materials
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

es en pt
Política de cookies Cookies policy Política de cookies
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.